Patents Assigned to Ospedale San Raffaele S.r.L.
-
Patent number: 11957713Abstract: The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.Type: GrantFiled: October 16, 2017Date of Patent: April 16, 2024Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., POLITECNICO DI MILANO, FONDAZIONE TELETHON ETS, DANA-FARBER CANCER INSTITUTE, INCInventors: Alessandra Biffi, Marco Peviani, Davide Moscatelli, Alessia Capotondo, Rita Milazzo, Umberto Capasso Palmiero
-
Patent number: 11957747Abstract: An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.Type: GrantFiled: January 7, 2021Date of Patent: April 16, 2024Assignees: Ospedale San Raffaele S.r.l., Fondazione Telethon ETSInventors: Alessio Cantore, Angelo Leone Lombardo, Luigi Naldini
-
Publication number: 20230332081Abstract: A cartridge is adapted to house at least one biological sample therein, where the cartridge contains at least two overlapping layers, and the layers include at least one layer of highly hydrophobic, inert, and biocompatible material, with contact angle ?c?90°, hydrophobic layer, and optionally, at least one layer of double-sided adhesive material, where in the absence of the at least one layer of double-sided adhesive material, the overlapping layers are connected together by chemical and/or physical bonding, where each of the overlapping layers has at least one inner hole that is pervious when the layers overlap one another, and the at least one inner hole is closed by the at least one biological sample, where loaded in the cartridge.Type: ApplicationFiled: August 13, 2021Publication date: October 19, 2023Applicants: POLITECNICO DI MILANO, OSPEDALE SAN RAFFAELE S.R.L.Inventors: Gianfranco Beniamino FIORE, Monica SONCINI, Marco PIOLA, Lorenzo Pietro COPPADORO, Chiara FOGLIENI, Maria LOMBARDI
-
Patent number: 11753643Abstract: A gene vector comprising a miRNA sequence target.Type: GrantFiled: June 10, 2018Date of Patent: September 12, 2023Assignees: OSPEDALE SAN RAFFAELE S.R.L., FONDAZIONE TELETHONInventors: Luigi Naldini, Brian Brown
-
Publication number: 20230226304Abstract: A stand-alone continuous positive airways pressure, CPAP, apparatus having a face-mask and a connected electro-mechanical device to supply air to the face-mask is disclosed. The electro-mechanical device includes a pneumatic channel for flowing air to be delivered to the face mask and a control unit for managing the air pressure of the air inside the pneumatic channel. The CPAP apparatus includes a turbine fan, located in the electro-mechanical device housing, connected to the control unit for pressurizing atmospheric air. The pneumatic channel includes an inlet portion located upstream of the turbine fan to receive atmospheric air, and an outlet portion located downstream of the turbine fan to deliver the pressurized air to the face-mask through an outlet opening. The pneumatic channel also longitudinally extends from the inlet portion to the outlet portion.Type: ApplicationFiled: May 4, 2021Publication date: July 20, 2023Applicants: OSPEDALE SAN RAFFAELE S.R.L., POLITECNICO DI MILANOInventors: Giovanni LANDONI, Alberto ZANGRILLO, Filippo CONSOLO, Alberto REDAELLI, Gianfranco Beniamino FIORE, Alessandro CAIMI
-
Publication number: 20230181719Abstract: The present invention relates to a conjugate comprising a first peptide of sequence CNGRCG (SEQ ID NO: 1) linked to the N-terminus of a protein and a compound X linked to the N-terminus of said peptide and to related medical uses.Type: ApplicationFiled: March 19, 2021Publication date: June 15, 2023Applicant: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Flavio CURNIS, Angelo CORTI, Andrès J. M. FERRERI
-
Publication number: 20230181621Abstract: The present invention relates to an inhibitor of asparagine synthase for use for the treatment of a disorder characterized by renal and/or liver cyst formation and relative pharmaceutical composition.Type: ApplicationFiled: September 4, 2019Publication date: June 15, 2023Applicant: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Alessandra BOLETTA, Christine PODRINI, Isaline Severine ROWE
-
Publication number: 20230167407Abstract: The present invention refers to a method to produce a T cell with advantageous properties. The invention also refers to a T cell or an engineered T cell produced by the method and its use in therapy.Type: ApplicationFiled: April 28, 2021Publication date: June 1, 2023Applicant: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Barbara CAMISA, Monica CASUCCI, Silvia ARCANGELI, Claudia MEZZANOTTE, Laura FALCONE, Maria Chiara BONINI
-
Publication number: 20230151027Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.Type: ApplicationFiled: February 9, 2021Publication date: May 18, 2023Applicants: Ospedale San Raffaele S.r.l., Istituto Nazionale Genetica Molecolare - INGMInventors: Romano DI FABIO, Vincenzo SUMMA, Leda Ivanova BENCHEVA, Raffaele DE FRANCESCO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Adolfo PRANDI, Marilenia DE MATTEO, Pietro RANDAZZO
-
Publication number: 20230134843Abstract: The present invention refers to an inhibitor of substance P and/or of its receptor for use in the treatment and/or prevention of stem cell deficiency. Preferably the inhibitor is an NK1 antagonist. Preferably the stem cell deficiency is a corneal epithelial stem cell deficiency. The invention also refers to pharmaceutical compositions containing the inhibitor for use in the treatment and/or prevention of stem cell deficiency.Type: ApplicationFiled: March 11, 2021Publication date: May 4, 2023Applicant: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Giulio FERRARI, Paolo RAMA
-
Patent number: 11597755Abstract: TCR AND PEPTIDES A T-cell receptor (TCR), which binds to a Wilms tumour 1 protein (WT1) peptide when presented by a major histocompatibility complex (MHC).Type: GrantFiled: April 24, 2018Date of Patent: March 7, 2023Assignees: Ospedale San Raffaele S.r.l., Fondazione Centro San RaffaeleInventors: Maria Chiara Bonini, Eliana Ruggiero, Zulma Irene Magnani, Luca Aldo Edoardo Vago, Attilio Bondanza, Fabio Ciceri
-
Publication number: 20230066287Abstract: The present invention relates to methods for the screening, diagnosis and/or prognosis of renal cell carcinoma. The methods of the invention are based on the determination of expression profiles of sets of miRNAs representative for renal cell carcinoma optionally associated with genotype analysis, in particular of uromodulin SNP variants. The invention also refers to a kit to perform such methods.Type: ApplicationFiled: January 16, 2020Publication date: March 2, 2023Applicant: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Francesco TREVISANI, Alessandra CINQUE, Alessandro LARCHER, Luca RAMPOLDI, Domenico FICHERA, Francesco RIPA
-
Patent number: 11548936Abstract: The present invention provides compositions and methods for the treatment or prevention of a lysosomal disease or disorder involving increasing the level, expression, or activity of a metallothionein polypeptide or polynucleotide in the subject.Type: GrantFiled: January 16, 2018Date of Patent: January 10, 2023Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., DANA-FARBER CANCER INSTITUTE, INC., FONDAZIONE TELETHONInventors: Alessandra Biffi, Eleonora Cavalca
-
Publication number: 20220402980Abstract: The present invention refers to chromogranin A-derived peptides that are potent dual ligands for integrins ?v?6 and av?8, their therapeutic and diagnostic uses and relative compositions.Type: ApplicationFiled: November 16, 2020Publication date: December 22, 2022Applicant: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Flavio CURNIS, Angelo CORTI, Giovanna MUSCO, Michela GHITTI, Francesca NARDELLI, Alessandro GORI
-
Patent number: 11407996Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.Type: GrantFiled: April 15, 2019Date of Patent: August 9, 2022Assignees: Ospedale San Raffaele S.r.l., Fondazione TelethonInventors: Alessandra Biffi, Bernhard Rudolf Gentner, Luigi Naldini
-
Publication number: 20220241241Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.Type: ApplicationFiled: May 25, 2020Publication date: August 4, 2022Applicants: ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM, OSPEDALE SAN RAFFAELE S.R.L., IRBM S.P.A.Inventors: Raffaele DE FRANCESCO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Romano DI FABIO, Vincenzo SUMMA, Adolfo PRANDI, Pietro RANDAZZO, Leda IVANOVA BENCHEVA, Marilenia DE MATTEO, Luca FERRANTE, Davide GORNATI, Alessandro GRILLO
-
Patent number: 11395835Abstract: It is described in vitro methods for expanding, detecting or isolating rare populations of antigen specific memory T cells. It is also described an in vitro method for obtaining a genetically modified memory T cell population. Uses of cells so obtained are also disclosed.Type: GrantFiled: May 4, 2018Date of Patent: July 26, 2022Assignee: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Maria Chiara Bonini, Attilio Bondanza
-
Patent number: 11360087Abstract: Use of (i) an anti-CD3 antibody, (ii) an anti-CD56 antibody, (iii) an anti-CD14 antibody, (iv) an anti-CD38 antibody, (v) an anti-CD45 antibody, (vi) an anti-CD90 antibody, (vii) an anti-CD135 antibody, (viii) an anti-CD10 antibody, (ix) an anti-CD11c antibody, (x) an anti-CD19 antibody, (xi) an anti-CD34 antibody, (xii) an anti-CD45RA antibody, (xiii) an anti-CD7 antibody, (xiv) an anti-CD71 antibody, (xv) an anti-CD41/CD61 complex antibody or an anti-CD41 antibody and/or an anti-CD61 antibody (xvi) an anti-CD33 antibody and/or an anti-CD66b antibody, for identifying hematopoietic cell subtypes in an isolated sample, determining the relative frequency of hematopoietic cell subtypes in an isolated sample and/or quantifying the number of cells within hematopoietic cell subtypes in an isolated sample, wherein each of (i) to (xvi) is labelled with a different fluorochrome, wherein when (xvi) is an anti-CD33 antibody and an anti-CD66b antibody, the anti-CD33 antibody and anti-CD66b are labelled with the same fluoType: GrantFiled: October 17, 2017Date of Patent: June 14, 2022Assignees: Ospedale San Raffaele S.R.L., Fondazione TelethonInventors: Luca Basso-Ricci, Luca Biasco, Alessandro Aiuti
-
Publication number: 20220110943Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.Type: ApplicationFiled: August 9, 2019Publication date: April 14, 2022Applicants: OSPEDALE SAN RAFFAELE S.R.L., IRBM S.P.A., PROMIDIS S.R.L., ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGMInventors: Raffaele DE FRANCESCO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Romano DI FABIO, Vincenzo SUMMA, Adolfo PRANDI, Pietro RANDAZZO, Davide GORNATI, Alessandro GRILLO, Luca FERRANTE, Leda Ivanova BENCHEVA, Marilenia DE MATTEO, Marco FERRARA
-
Publication number: 20220098252Abstract: The present invention relates to an inhibitor of DUX4 and its use, in particular in the prevention and/or treatment of a condition associated with an aberrant expression and/or function of at least one DUX4 protein and/or of at least one DUX4 fusion protein. Preferably the inhibitor is MATRIN-3 (MATR3), fragment, variant, fusion, or conjugate thereof. The invention also relates to a pharmaceutical composition comprising such inhibitor, to vector and nucleic acids.Type: ApplicationFiled: January 27, 2020Publication date: March 31, 2022Applicants: OSPEDALE SAN RAFFAELE S.R.L., FONDAZIONE CENTRO SAN RAFFAELEInventors: Davide GABELLINI, Roberto GIAMBRUNO, Valeria RUNFOLA, Claudia CARONNI